company background image
SWTX logo

SpringWorks Therapeutics NasdaqGS:SWTX Stock Report

Last Price

US$50.10

Market Cap

US$3.7b

7D

-0.3%

1Y

98.1%

Updated

27 Mar, 2024

Data

Company Financials +

SpringWorks Therapeutics, Inc.

NasdaqGS:SWTX Stock Report

Market Cap: US$3.7b

SWTX Stock Overview

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer.

SWTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

SpringWorks Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for SpringWorks Therapeutics
Historical stock prices
Current Share PriceUS$50.10
52 Week HighUS$53.92
52 Week LowUS$18.00
Beta0.83
1 Month Change3.34%
3 Month Change34.53%
1 Year Change98.10%
3 Year Change-31.90%
5 Year Changen/a
Change since IPO121.39%

Recent News & Updates

Recent updates

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Sep 20
We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate

Jun 07
We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate

We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Feb 22
We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation

Nov 09
Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation

SpringWorks drops 21% as Allogene drops lead asset in combination study

Aug 10

SpringWorks Therapeutics GAAP EPS of -$1.41 misses by $0.15

Aug 04

Sizing Up SpringWorks Therapeutics

Jul 20

Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?

Jun 06
Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?

SpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data Releases

May 02

Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth

Dec 30
Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth

SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline

Dec 14

SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Strong Position To Grow Its Business

Sep 15
SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Strong Position To Grow Its Business

SpringWorks shows durable effect for neurofibroma therapy with long-term data

Jun 15

SpringWorks teams up with Seagen to evaluate nirogacestat combo in multiple myeloma

Jun 07

We're Interested To See How SpringWorks Therapeutics (NASDAQ:SWTX) Uses Its Cash Hoard To Grow

May 31
We're Interested To See How SpringWorks Therapeutics (NASDAQ:SWTX) Uses Its Cash Hoard To Grow

SpringWorks Therapeutics EPS misses by $0.11

May 06

SpringWorks Therapeutics announces C-level promotions

Dec 15

SpringWorks Therapeutics EPS misses by $0.02

Nov 12

Shareholder Returns

SWTXUS BiotechsUS Market
7D-0.3%0.9%0.4%
1Y98.1%10.3%28.8%

Return vs Industry: SWTX exceeded the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: SWTX exceeded the US Market which returned 29.5% over the past year.

Price Volatility

Is SWTX's price volatile compared to industry and market?
SWTX volatility
SWTX Average Weekly Movement7.6%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: SWTX's share price has been volatile over the past 3 months.

Volatility Over Time: SWTX's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017305Saqib Islamhttps://www.springworkstx.com

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas.

SpringWorks Therapeutics, Inc. Fundamentals Summary

How do SpringWorks Therapeutics's earnings and revenue compare to its market cap?
SWTX fundamental statistics
Market capUS$3.69b
Earnings (TTM)-US$325.10m
Revenue (TTM)US$5.45m

677.7x

P/S Ratio

-11.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SWTX income statement (TTM)
RevenueUS$5.45m
Cost of RevenueUS$422.00k
Gross ProfitUS$5.03m
Other ExpensesUS$330.13m
Earnings-US$325.10m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-4.41
Gross Margin92.25%
Net Profit Margin-5,968.50%
Debt/Equity Ratio0%

How did SWTX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.